Anthony George Letai

Anthony George Letai, M.D., Ph.D.

Professor of Medicine

617-632-2348

Publications

Publications View

BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics.

Authors: Authors: Touzeau C, Ryan J, Guerriero J, Moreau P, Chonghaile TN, Le Gouill S, Richardson P, Anderson K, Amiot M, Letai A.
Leukemia 2016-03-01
View full abstract on Pubmed

Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice.

Authors: Authors: Etchin J, Montero J, Berezovskaya A, Le BT, Kentsis A, Christie AL, Conway AS, Chen WC, Reed C, Mansour MR, Ng CE, Adamia S, Rodig SJ, Galinsky IA, Stone RM, Klebanov B, Landesman Y, Kauffman M, Shacham S, Kung AL, Wang JC, Letai A, Look AT.
Leukemia 2016-01-01
View full abstract on Pubmed

To Prime, or Not to Prime: That Is the Question.

Authors: Authors: Potter DS, Letai A.
Cold Spring Harb Symp Quant Biol 2016-01-01
View full abstract on Pubmed

MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.

Authors: Authors: Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Chonghaile TN, Gonzalo O, Qiu Y, Jeremias I, Debose L, O'Brien E, Ma H, Zhou P, Jacamo R, Park E, Coombes KR, Zhang N, Thomas DA, O'Brien S, Kantarjian HM, Leverson JD, Kornblau SM, Andreeff M, Müschen M, Zweidler-McKay PA, Mulloy JC, Letai A, Milne TA, Konopleva M.
Cell Rep 2015-12-29
View full abstract on Pubmed

Precision medicine for cancer with next-generation functional diagnostics.

Authors: Authors: Friedman AA, Letai A, Fisher DE, Flaherty KT.
Nat Rev Cancer 2015-12-01
View full abstract on Pubmed

Cell Death and Cancer Therapy: Don't Forget to Kill the Cancer Cell!

Authors: Authors: Letai A.
Clin Cancer Res 2015-11-15
View full abstract on Pubmed

Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma.

Authors: Authors: Bhatt S, Matthews J, Parvin S, Sarosiek KA, Zhao D, Jiang X, Isik E, Letai A, Lossos IS.
Blood 2015-09-24
View full abstract on Pubmed

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.

Authors: Authors: Wu SC, Li LS, Kopp N, Montero J, Chapuy B, Yoda A, Christie AL, Liu H, Christodoulou A, van Bodegom D, van der Zwet J, Layer JV, Tivey T, Lane AA, Ryan JA, Ng SY, DeAngelo DJ, Stone RM, Steensma D, Wadleigh M, Harris M, Mandon E, Ebel N, Andraos R, Romanet V, Dölemeyer A, Sterker D, Zender M, Rodig SJ, Murakami M, Hofmann F, Kuo F, Eck MJ, Silverman LB, Sallan SE, Letai A, Baffert F, Vangrevelinghe E, Radimerski T, Gaul C, Weinstock DM.
Cancer Cell 2015-07-13
View full abstract on Pubmed

Potent and specific peptide inhibitors of human pro-survival protein Bcl-xL.

Authors: Authors: Dutta S, Ryan J, Chen TS, Kougentakis C, Letai A, Keating AE.
J Mol Biol 2015-03-27
View full abstract on Pubmed

Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy.

Authors: Authors: Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, Jänne PA, Amrein PC, Cichowski K, Drapkin R, Letai A.
Cell 2015-02-26
View full abstract on Pubmed